Evolution of endocrine adjuvant therapy for early breast cancer

Bibliography

• Harvey JM, Clark GM, Osborne CK, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81
   PubMed Web of Science ®Google Scholar
• Abe O, Abe R, Enomoto K, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
   PubMed Web of Science ®Google Scholar
• Lønning PE. Additive endocrine therapy for advanced breast cancer – back to the future. Acta Oncol 2009;48:1092-101
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Bajetta E, Dirix LY, Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399-411
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovick M, Sun Y, Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol 2003;21:2101-9
   PubMed Web of Science ®Google Scholar
• Ingle JN, Ahmann DL, Green SJ, Randomized clinical trial of diethylstilstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981;304:16-21
   PubMed Web of Science ®Google Scholar
• Lundgren S. Progestins in breast cancer treatment. Acta Oncol 1992;31:709-22
   PubMed Web of Science ®Google Scholar
• Lønning PE, Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 1988;35:685-710
   PubMed Web of Science ®Google Scholar
• McGuire WL. Steroid receptors in human breast cancer. Cancer Res 1978;38:4289-91
   PubMed Web of Science ®Google Scholar
• Degenshein GA, Bloom N, Tobin E. The value of progesterone receptor assays in the management of advanced breast cancer. Cancer 1980;46:2789-93
   PubMed Web of Science ®Google Scholar
• McGuire WL, Horwitz KB, Pearson OH, Current status of estrogen and progesterone receptors in breast cancer. Cancer 1977;39:2934-47
   PubMed Web of Science ®Google Scholar
• Allred DC, Harvey JM, Berardo M, Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68
   PubMed Web of Science ®Google Scholar
• Bardou VJ, Arpino G, Elledge RM, Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9
   PubMed Web of Science ®Google Scholar
• Horwitz KB, McGuire WL. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975;189:726-7
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cuzick J, Wale C, Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512-7
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Coop A, Singh B, Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16
   PubMed Web of Science ®Google Scholar
• Dowsett M, Allred C, Knox J, Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008;26:1059-65
   PubMed Web of Science ®Google Scholar
• Viale G, Regan MM, Maiorano E, Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;25:3846-52
   PubMed Web of Science ®Google Scholar
• Sørlie T, Perou CM, Tibshirani R, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Nat Acad Sci 2001;98:10869-74
   PubMed Web of Science ®Google Scholar
• Sørlie T, Tibshirani R, Parker J, Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23
   PubMed Web of Science ®Google Scholar
• Lønning PE, Sørlie T, Børresen-Dale A-L. Genomics in breast cancer – therapeutic implications? Nat Clin Pract Oncol 2005;2:26-33
   PubMedGoogle Scholar
• Lippman M, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976;36:4595-601
   PubMed Web of Science ®Google Scholar
• Masamura S, Santner SJ, Heitjan DF, Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25
   PubMed Web of Science ®Google Scholar
• Dowsett M, Martin LA, Smith I, Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 2005;95:167-72
   PubMed Web of Science ®Google Scholar
• Lønning PE, Taylor PD, Anker G, High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine treatment. Breast Cancer Res Treat 2001;67:111-6
   PubMed Web of Science ®Google Scholar
• Flageng MH, Moi LLH, Dixon JM, Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer 2009;101:1253-60
   PubMed Web of Science ®Google Scholar
• Jordan VC. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer - survival or death? J Clin Oncol 2008;26:3073-82
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Aromatase inhibitors: future directions. J Steroid Biochem Mol Biol 2005;95:183-7
   PubMed Web of Science ®Google Scholar
• Yue W, Fan P, Wang JP, Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007;106:102-10
   PubMed Web of Science ®Google Scholar
• Carlomagno C, Perrone F, Gallo C, C-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702-8
   PubMed Web of Science ®Google Scholar
• Johnston S, Pegram M, Press M, Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR plus ) metastatic breast cancer (MBC): first results from the EGF30008 trial. Cancer Res 2009;69:74S-5S
   Web of Science ®Google Scholar
• Rasmussen BB, Regan MM, Lykkesfeldt AE, Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008;9:23-8
   PubMed Web of Science ®Google Scholar
• Dowsett M, Smith IE, Ebbs SR, Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99:167-70
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Tao Y, Luo JQ, Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380-8
   PubMed Web of Science ®Google Scholar
• Viale G, Giobbie-Hurder A, Regan MM, Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results From Breast International Group Trial 1 – 98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;26:5569-75
   PubMed Web of Science ®Google Scholar
• Kuiper GG, Enmark E, Pelto-Huikko, Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-30
   PubMed Web of Science ®Google Scholar
• Mosselman S, Polman J, Dijkema R. ER beta identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53
   PubMed Web of Science ®Google Scholar
• Speirs V. The evolving role of oestrogen receptor beta in clinical breast cancer. Breast Cancer Res 2008;10(5):111
   PubMedGoogle Scholar
• Zhang WH, Andersson S, Cheng GJ, Update on estrogen signaling. FEBS Lett 2003;546:17-24
   PubMed Web of Science ®Google Scholar
• Honma N, Horii R, Iwase T, Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008;26:3727-34
   PubMedGoogle Scholar
• Shaaban AM, Green AR, Karthik S, Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008;14:5228-35
   PubMed Web of Science ®Google Scholar
• Lønning PE, Lien E. Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol Haematol 1995;21:158-93
   PubMed Web of Science ®Google Scholar
• Stearns V, Johnson MD, Rae JM, Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64
   PubMed Web of Science ®Google Scholar
• Schroth W, Antoniadou L, Fritz P, Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-93
   PubMed Web of Science ®Google Scholar
• Goetz MP, Knox SK, Suman VJ, The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-21
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Mushiroda T, Sasa M, Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008;99:995-9
   PubMed Web of Science ®Google Scholar
• Lash TL, Lien EA, Sorensen HT, Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009;10:825-33
   PubMed Web of Science ®Google Scholar
• Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009;9:576-86
   PubMed Web of Science ®Google Scholar
• Ma CX, Adjei AA, Salavaggione OE, Human aromatase: gene resequencing and functional genomics. Cancer Res 2005;65:11071-82
   PubMed Web of Science ®Google Scholar
• Colomer R, Monzo M, Tusquets I, A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008;14:811-6
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Davies C, Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996;348:1189-96
   PubMed Web of Science ®Google Scholar
• Cuzick J, Ambroisine L, Davidson N, Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-23
   PubMed Web of Science ®Google Scholar
• Jonat W, Kaufmann M, Sauerbrei W, Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002;20:4628-35
   PubMed Web of Science ®Google Scholar
• Jakesz R, Hausmaninger H, Kubista E, Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer–Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20:4621-7
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J, Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90
   PubMed Web of Science ®Google Scholar
• Stewart HJ, Prescott RJ, Forrest APM. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93:456-62
   PubMed Web of Science ®Google Scholar
• Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996;88:1828-33
   PubMed Web of Science ®Google Scholar
• Peto R, Davies C. ATLAS (adjuvant tamoxifen, longer against shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women-preliminary results. Breast Cancer Res Treat 2008;109:586
   Web of Science ®Google Scholar
• Klijn JGM, Beex LVAM, Mauriac L, Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000;92:903-11
   PubMed Web of Science ®Google Scholar
• Klijn JGM, Blamey RW, Boccardo F, Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53
   PubMed Web of Science ®Google Scholar
• Caleffi M, Fentiman IS, Clark GM, Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol 1988;119:335-9
   PubMed Web of Science ®Google Scholar
• Groom GV, Griffiths K. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 1976;70:421-8
   PubMed Web of Science ®Google Scholar
• Baum M, Buzdar AU, Cuzick J, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9
   PubMed Web of Science ®Google Scholar
• Lønning PE, Jacobs S, Jones A, The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 1991;63:789-93
   PubMed Web of Science ®Google Scholar
• Fex G, Adielsson G, Mattson W. Oestrogen-like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocrinol 1981;97:109-13
   PubMedGoogle Scholar
• Lønning PE, Hall K, Aakvaag A, Influence of tamoxifen on the plasma levels of insulin-like growth factor I and Insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 1992;52:4719-23
   PubMed Web of Science ®Google Scholar
• Buzdar A, Hayes D, El-Khoudary A, Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 2002;73:161-75
   PubMed Web of Science ®Google Scholar
• Bruning PF. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer. 1992;28A:1404-7
   PubMed Web of Science ®Google Scholar
• Lønning PE, Johannessen DC, Lien EA, Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 1995;52:491-6
   PubMed Web of Science ®Google Scholar
• Geisler J, Haarstad H, Gundersen S, Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. J Endocrinol 1995;146:359-63
   PubMed Web of Science ®Google Scholar
• Helle SI, Anker G, Tally M, Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Mol Biol 1996;57:167-71
   PubMed Web of Science ®Google Scholar
• Geisler J, Ekse D, Hösch S, Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 1995;55:193-5
   PubMed Web of Science ®Google Scholar
• Decensi A, Robertson C, Viale G, A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-90
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Schippinger W, Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-82
   PubMed Web of Science ®Google Scholar
• Lønning PE. Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)? J Clin Oncol 2008;26:4859-61
   PubMed Web of Science ®Google Scholar
• Kohno N. Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future. Int J Clin Oncol 2008;13:18-23
   PubMed Web of Science ®Google Scholar
• Yuasa T, Kimura S, Ashihara E, Zoledronic acid – a multiplicity of anti-cancer action. Curr Med Chem 2007;14:2126-35
   PubMed Web of Science ®Google Scholar
• Jones DH, Nakashima T, Sanchez OH, Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440:692-6
   PubMed Web of Science ®Google Scholar
• Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006;24:5769-79
   PubMed Web of Science ®Google Scholar
• Parulekar WR, Day AG, Ottaway JA, Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study – NCICCTG MA.5. J Clin Oncol 2005;23:6002-8
   PubMed Web of Science ®Google Scholar
• Petrek JA, Naughton MJ, Case LD, Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006;24:1045-51
   PubMed Web of Science ®Google Scholar
• Lønning PE. Adjuvant endocrine treatment of early breast cancer. Hematol Oncol Clin North Am 2007;21:223-38
   PubMed Web of Science ®Google Scholar
• Lønning PE, Geisler J. Indications and limitations of third-generation aromatase inhibitors. Expert Opin Invest Drugs 2008;17:723-39
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF, Survival and safety of exemestane versus tamoxifen after 2 – 3 years tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 2007;369:559-70
   PubMed Web of Science ®Google Scholar
• Jonat W, Gnant M, Boccardo F, Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormonesensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006;7:991-6
   PubMed Web of Science ®Google Scholar
• Pocock SJ. The simplest statistical test: how to check for a difference between treatments. BMJ 2006;332:1256-8
   PubMed Web of Science ®Google Scholar
• Thurlimann B, Keshaviah A, Coates AS, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57
   PubMed Web of Science ®Google Scholar
• Forbes JF, Cuzick J, Buzdar A, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53
   PubMed Web of Science ®Google Scholar
• Mouridsen HT, Giobbie-Hurder A, Mauriac L, BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Cancer Res 2009;69:66S-7S
   Web of Science ®Google Scholar
• Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-76
   PubMed Web of Science ®Google Scholar
• Rea D, Hasenburg A, Seynaeve C, Five years of exemestane as initial therapy compared to 2-3 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer [abstract 11]. Cancer Res 2009;69:487s
   Web of Science ®Google Scholar
• Lønning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2 – 3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 2006;17:217-25
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pater JL, Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:1948-55
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72
   PubMed Web of Science ®Google Scholar
• Baselga J, Tripathy D, Mendelsohn J, Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999;26:78-83
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
   PubMed Web of Science ®Google Scholar
• Slamon DJ, LeylandJones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, Molecular portraits of human breast tumours. Nature 2000;406:747-52
   PubMed Web of Science ®Google Scholar
• Arpino G, Weiss H, Lee AV, Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97:1254-61
   PubMed Web of Science ®Google Scholar
• Konecny G, Pauletti G, Pegram M, Quantitative association between, HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12
   PubMed Web of Science ®Google Scholar
• Kaufman B, Mackey J, Clemens M, Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized Phase III TAnDEM study. J Clin Oncol 2009;27:5529-37
   PubMed Web of Science ®Google Scholar
• Lønning PE. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer 2009;45:527-35
   PubMed Web of Science ®Google Scholar